Also trades as: ACST.V (TSXV) · $vol 0M
ACST NASDAQ
Acasti Pharma Inc.
1W: +5.5%
1M: -3.5%
3M: +38.4%
1Y: +56.9%
3Y: -62.6%
5Y: -96.7%
$3.37
Last traded 2024-11-22 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
#602
of 1064
Biotechnology
Technical Signal Map
3 Bullish
1 Neutral
9 Bearish
ACST
$30M
Acasti Pharma Inc.
N/A
0
ABCL
$4.2B
AbCellera Biologics Inc.
BULLISH
+91
ENGN
$130M
enGene Holdings Inc.
BULLISH
+58
BCTX
$50M
BriaCell Therapeutics Corp.
BULLISH
+44
ARCH.V
$60M
Arch Biopartners Inc.
BEARISH
-59
AUPH
$2.0B
Aurinia Pharmaceuticals Inc.
BEARISH
-68
EPRX
$400M
Eupraxia Pharmaceuticals Inc.
BEARISH
-68
XENE
$3.8B
Xenon Pharmaceuticals Inc.
BEARISH
-78
PMN
$80M
ProMIS Neurosciences, Inc.
BEARISH
-78
MIST
$100M
Milestone Pharmaceuticals Inc.
BEARISH
-91
MSLE
$250M
Satellos Bioscience Inc.
BEARISH
-100
NGEN
$140M
NervGen Pharma Corp. Common stock
BEARISH
-100
HBP.TO
$70M
Helix BioPharma Corp.
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| ACST Acasti Pharma Inc. | $30M | -2.9 | -14.5 | -9.5 | — | -100.0 | 2 | N/A | 56.9 |
| ABCL AbCellera Biologics Inc. | $4.2B | -25.4 | -17.3 | -36.2 | -1368.6 | 101.3 | 4 | BULLISH | 130.5 |
| ENGN enGene Holdings Inc. | $130M | -6.9 | -2.3 | 134.1 | — | -100.0 | 2 | BULLISH | -74.5 |
| BCTX BriaCell Therapeutics Corp. | $50M | -0.3 | -179.9 | -2435.2 | — | — | 2 | BULLISH | -67.9 |
| ARCH.V Arch Biopartners Inc. | $60M | -19.5 | 73.9 | 162.4 | — | 100.0 | 2 | BEARISH | -49.1 |
| AUPH Aurinia Pharmaceuticals Inc. | $2.0B | 6.7 | 66.1 | 127.2 | 45.0 | 19.8 | 7 | BEARISH | 38.9 |
| EPRX Eupraxia Pharmaceuticals Inc. | $400M | -7.1 | -68.6 | 8742.2 | — | — | 3 | BEARISH | 19.3 |
| XENE Xenon Pharmaceuticals Inc. | $3.8B | -8.0 | -43.6 | -109.7 | — | -100.0 | 3 | BEARISH | -2.8 |
| PMN ProMIS Neurosciences, Inc. | $80M | -0.6 | -172.3 | 844.3 | — | — | 2 | BEARISH | -17.5 |
| MIST Milestone Pharmaceuticals Inc. | $100M | -1.2 | -35522.6 | 587.8 | -5118.8 | — | 5 | BEARISH | -52.1 |
| MSLE Satellos Bioscience Inc. | $250M | — | — | — | — | — | — | BEARISH | — |
| NGEN NervGen Pharma Corp. Common stock | $140M | — | — | — | — | — | — | BEARISH | — |
| HBP.TO Helix BioPharma Corp. | $70M | -22.3 | -50.0 | -21.4 | — | — | 3 | BEARISH | -29.6 |
| ACST Acasti Pharma Inc. | $30M | -2.9 | -14.5 | -9.5 | — | -100.0 | 2 | N/A | 56.9 |
| ABCL AbCellera Biologics Inc. | $4.2B | -25.4 | -17.3 | -36.2 | -1368.6 | 101.3 | 4 | BULLISH | 130.5 |
| ENGN enGene Holdings Inc. | $130M | -6.9 | -2.3 | 134.1 | — | -100.0 | 2 | BULLISH | -74.5 |
| BCTX BriaCell Therapeutics Corp. | $50M | -0.3 | -179.9 | -2435.2 | — | — | 2 | BULLISH | -67.9 |
| ARCH.V Arch Biopartners Inc. | $60M | -19.5 | 73.9 | 162.4 | — | 100.0 | 2 | BEARISH | -49.1 |
| AUPH Aurinia Pharmaceuticals Inc. | $2.0B | 6.7 | 66.1 | 127.2 | 45.0 | 19.8 | 7 | BEARISH | 38.9 |
| EPRX Eupraxia Pharmaceuticals Inc. | $400M | -7.1 | -68.6 | 8742.2 | — | — | 3 | BEARISH | 19.3 |
| XENE Xenon Pharmaceuticals Inc. | $3.8B | -8.0 | -43.6 | -109.7 | — | -100.0 | 3 | BEARISH | -2.8 |
| PMN ProMIS Neurosciences, Inc. | $80M | -0.6 | -172.3 | 844.3 | — | — | 2 | BEARISH | -17.5 |
| MIST Milestone Pharmaceuticals Inc. | $100M | -1.2 | -35522.6 | 587.8 | -5118.8 | — | 5 | BEARISH | -52.1 |
| MSLE Satellos Bioscience Inc. | $250M | — | — | — | — | — | — | BEARISH | — |
| NGEN NervGen Pharma Corp. Common stock | $140M | — | — | — | — | — | — | BEARISH | — |
| HBP.TO Helix BioPharma Corp. | $70M | -22.3 | -50.0 | -21.4 | — | — | 3 | BEARISH | -29.6 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
ACST vs Benchmarks
ROIC
Revenue Growth
P/E Ratio
ROE
Piotroski F